$NBIX
NEUROCRINE BIOSCIENCES INC Stock $nbix

$nbix Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000091447521000058 Filed on November 01, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q4
Revenue	$312.0M	$296.0M	$247.9M
YoY Change	25.86%	14.51%	1.56%
Cost Of Revenue	$4.100M	$4.200M	$2.900M
YoY Change	41.38%	55.56%	16.0%
Gross Profit	$307.9M	$291.8M	$245.0M
YoY Change	25.67%	14.07%	1.45%
Gross Profit Margin	98.69%	98.58%	98.83%
Selling, General & Admin	$156.5M	$154.6M	$106.5M
YoY Change	46.95%	37.42%	5.24%
% of Gross Profit	50.83%	52.98%	43.47%
Research & Development	$87.40M	$92.70M	$66.70M
YoY Change	31.03%	34.15%	20.4%
% of Gross Profit	28.39%	31.77%	27.22%
Depreciation & Amortization	$3.000M	$2.800M	$2.200M
YoY Change	36.36%	27.27%	4.76%
% of Gross Profit	0.97%	0.96%	0.9%
Operating Expenses	$243.9M	$247.3M	$176.1M
YoY Change	38.5%	-18.33%	-9.83%
Operating Profit	$64.00M	$44.50M	$68.90M
YoY Change	-7.11%	-200.45%	49.13%
Interest Expense	$22.50M	$6.600M	-$11.70M
YoY Change	-292.31%	-22.35%	15.84%
% of Operating Profit	35.16%	14.83%	-16.98%
Other Income/Expense, Net		-$14.00M
YoY Change		9.38%
Pretax Income	-$13.80M	$30.50M	$41.70M
YoY Change	-133.09%	-153.42%	8.03%
Income Tax	-$6.500M	$8.000M	-$306.2M
% Of Pretax Income		26.23%	-734.29%
Net Earnings	-$7.300M	$22.50M	$347.9M
YoY Change	-102.1%	-139.06%	923.24%
Net Earnings / Revenue	-2.34%	7.6%	140.34%
Basic Earnings Per Share		$0.24	$3.72
Diluted Earnings Per Share	-$76.92K	$0.23	$3.58
COMMON SHARES
Basic Shares Outstanding	94.87M shares	94.70M shares	93.50M shares
Diluted Shares Outstanding		97.70M shares	97.20M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$711.3M	$765.9M	$801.0M
YoY Change	-11.2%	-18.93%	19.46%
Cash & Equivalents	$340.8M	$311.1M	$187.1M
Short-Term Investments	$370.5M	$454.8M	$613.9M
Other Short-Term Assets	$45.50M	$50.50M	$30.10M
YoY Change	51.16%	45.53%	81.33%
Inventory	$30.50M	$25.50M	$28.00M
Prepaid Expenses
Receivables	$185.5M	$163.8M	$157.1M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$972.8M	$1.006B	$1.016B
YoY Change	-4.27%	-13.07%	22.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$58.60M	$51.10M	$44.60M
YoY Change	31.39%	18.84%	6.44%
Goodwill	$0.00
YoY Change
Intangibles	$0.00
YoY Change
Long-Term Investments	$624.4M	$549.0M	$265.3M
YoY Change	135.36%	143.89%	-25.37%
Other Assets	$4.400M	$3.200M	$6.400M
YoY Change	-31.25%	-5.88%
Total Long-Term Assets	$1.100B	$1.012B	$718.5M
YoY Change	53.05%	192.62%	51.26%
TOTAL ASSETS
Total Short-Term Assets	$972.8M	$1.006B	$1.016B
Total Long-Term Assets	$1.100B	$1.012B	$718.5M
Total Assets	$2.073B	$2.017B	$1.735B
YoY Change	19.47%	34.25%	32.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$225.8M	$205.9M	$168.7M
YoY Change	33.85%	20.76%	19.39%
Accrued Expenses	$16.50M	$15.50M	$10.30M
YoY Change	60.19%	59.79%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$245.8M	$225.9M	$186.5M
YoY Change	31.8%	-63.03%	-67.01%
LONG-TERM LIABILITIES
Long-Term Debt	$335.1M	$330.7M	$317.9M
YoY Change	5.41%
Other Long-Term Liabilities	$12.30M	$8.300M	$9.700M
YoY Change	26.8%	93.02%	-43.27%
Total Long-Term Liabilities	$12.30M	$8.300M	$9.700M
YoY Change	26.8%	93.02%	-43.27%
TOTAL LIABILITIES
Total Short-Term Liabilities	$245.8M	$225.9M	$186.5M
Total Long-Term Liabilities	$12.30M	$8.300M	$9.700M
Total Liabilities	$698.5M	$671.3M	$608.5M
YoY Change	14.79%	-3.87%	-9.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$635.8M	-$628.5M	-$725.4M
YoY Change	-12.35%	-41.44%	-35.96%
Common Stock	$2.012B	$1.974B	$1.850B
YoY Change	8.74%	5.32%	4.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.374B	$1.346B	$1.126B
YoY Change
Total Liabilities & Shareholders Equity	$2.073B	$2.017B	$1.735B
YoY Change	19.47%	34.25%	32.83%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q4
OPERATING ACTIVITIES
Net Income	-$7.300M	$22.50M	$347.9M
YoY Change	-102.1%	-139.06%	923.24%
Depreciation, Depletion And Amortization	$3.000M	$2.800M	$2.200M
YoY Change	36.36%	27.27%	4.76%
Cash From Operating Activities	$4.200M	$61.80M	$88.90M
YoY Change	-95.28%	-453.14%	-13.35%
INVESTING ACTIVITIES
Capital Expenditures	-$8.900M	-$5.700M	-$4.500M
YoY Change	97.78%	1325.0%	60.71%
Acquisitions
YoY Change
Other Investing Activities	$32.60M	-$120.5M	-$143.2M
YoY Change	-122.77%	-570.7%	-12.31%
Cash From Investing Activities	$23.70M	-$126.2M	-$147.7M
YoY Change	-116.05%	-600.79%	-11.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.800M	7.500M	-179.4M
YoY Change	-101.0%	200.0%	-2557.53%
NET CHANGE
Cash From Operating Activities	4.200M	61.80M	88.90M
Cash From Investing Activities	23.70M	-126.2M	-147.7M
Cash From Financing Activities	1.800M	7.500M	-179.4M
Net Change In Cash	29.70M	-56.90M	-238.2M
YoY Change	-112.47%	-657.84%	323.09%
FREE CASH FLOW
Cash From Operating Activities	$4.200M	$61.80M	$88.90M
Capital Expenditures	-$8.900M	-$5.700M	-$4.500M
Free Cash Flow	$13.10M	$67.50M	$93.40M
YoY Change	-85.97%	-494.74%	-11.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0000914475
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	0-22705
	dei	Entity Registrant Name EntityRegistrantName	NEUROCRINE BIOSCIENCES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Address Address Line1 EntityAddressAddressLine1	12780 El Camino Real
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	33-0525145
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
	dei	City Area Code CityAreaCode	(858)
	dei	Local Phone Number LocalPhoneNumber	617-7600
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	NBIX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	94866693	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	311100000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	187100000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	454600000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	612400000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	454800000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	613900000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	163800000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	157100000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	25500000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	28000000.0	USD
CY2021Q3	us-gaap	Other Assets Current OtherAssetsCurrent	50500000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	258500000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	30100000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	1005700000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	1016200000	USD
CY2021Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	310400000	USD
CY2020Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	319400000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	513800000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	226700000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	513700000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	227100000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	97900000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	82800000	USD
CY2021Q3	us-gaap	Equity Securities Fv Ni Restricted EquitySecuritiesFvNiRestricted	35300000	USD
CY2020Q4	us-gaap	Equity Securities Fv Ni Restricted EquitySecuritiesFvNiRestricted	38200000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	51100000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	44600000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3200000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6400000	USD
CY2021Q3	us-gaap	Assets Assets	2017300000	USD
CY2020Q4	us-gaap	Assets Assets	1734700000	USD
CY2021Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	205900000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	168700000	USD
CY2021Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	20000000.0	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	17800000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	225900000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	186500000	USD
CY2021Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	330700000	USD
CY2020Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	317900000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	106400000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	94400000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8300000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9700000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	671300000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	296000000.0	USD
CY2020Q4	us-gaap	Liabilities Liabilities	608500000	USD
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000.0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000.0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	220000000.0	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	220000000.0	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	94800000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	94800000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	93500000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	93500000	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	100000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	100000	USD
CY2021Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1974000000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1849700000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	400000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1800000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-628500000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-725400000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	1346000000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1126200000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2017300000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1734700000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	821500000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	798000000.0	USD
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4200000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2700000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10200000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7200000	USD
CY2021Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	92700000	USD
CY2020Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	69100000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	240700000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	208300000	USD
CY2021Q3	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	USD
CY2020Q3	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	118500000	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	5000000.0	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	164500000	USD
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	154600000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	112500000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	426800000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	326800000	USD
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	251500000	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	302800000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	682700000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	706800000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	44500000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-44300000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	138800000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	91200000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	6600000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	8500000	USD
	us-gaap	Interest Expense InterestExpense	19200000	USD
	us-gaap	Interest Expense InterestExpense	25000000.0	USD
CY2021Q3	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-8200000	USD
CY2020Q3	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-7000000.0	USD
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-7500000	USD
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-12200000	USD
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
CY2020Q3	nbix	Investment Income And Other Net InvestmentIncomeAndOtherNet	2700000	USD
	nbix	Investment Income And Other Net InvestmentIncomeAndOtherNet	3100000	USD
	nbix	Investment Income And Other Net InvestmentIncomeAndOtherNet	11000000.0	USD
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-14000000.0	USD
CY2021Q3	nbix	Investment Income And Other Net InvestmentIncomeAndOtherNet	800000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-12800000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-23600000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-26200000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	30500000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-57100000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	115200000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	65000000.0	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000000.0	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	500000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	18300000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5600000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	22500000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-57600000	USD
	us-gaap	Net Income Loss NetIncomeLoss	96900000	USD
	us-gaap	Net Income Loss NetIncomeLoss	59400000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-300000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1400000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1400000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1800000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	22200000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-59000000.0	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	95500000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	61200000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.24
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.64
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.23
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.99
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.61
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94700000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	93300000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94500000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	93000000.0	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97700000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	93300000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97900000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	98000000.0	shares
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	1279200000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	22500000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-300000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	37100000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	7500000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	1346000000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	831200000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-57600000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1400000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	26700000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5400000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	804300000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1126200000	USD
	us-gaap	Net Income Loss NetIncomeLoss	96900000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1400000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	98600000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	25700000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	1346000000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	636900000	USD
	us-gaap	Net Income Loss NetIncomeLoss	59400000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1800000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	79000000.0	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	27200000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	804300000	USD
	us-gaap	Net Income Loss NetIncomeLoss	96900000	USD
	us-gaap	Net Income Loss NetIncomeLoss	59400000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	98600000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	79000000.0	USD
	us-gaap	Depreciation Depreciation	7900000	USD
	us-gaap	Depreciation Depreciation	6400000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	12100000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	15200000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	800000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1000000.0	USD
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-7500000	USD
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-12200000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	9000000.0	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	0	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	7700000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	1700000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6700000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	30300000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2500000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3400000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	37700000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	28100000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	21700000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	35300000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	252300000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	134000000.0	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	658700000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	399200000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	523900000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	557400000	USD
	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	4600000	USD
	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14500000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6400000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-153900000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	151800000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25700000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	27200000	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	100000	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25600000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	27200000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	124000000.0	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	313000000.0	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	190300000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115500000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	314300000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	428500000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	300000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1100000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	21600000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	4300000	USD
	us-gaap	Interest Paid Net InterestPaidNet	5800000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	3400000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	400000	USD
	nbix	Number Of Irish Subsidiaries NumberOfIrishSubsidiaries	2	subsidiary
CY2021Q3	nbix	Debt Securities Available For Sale Position Number Of Positions DebtSecuritiesAvailableForSalePositionNumberOfPositions	160	security
CY2021Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	82	security
CY2021Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	405800000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	400000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	95000000.0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	100000	USD
CY2021Q3	us-gaap	Interest Receivable Current InterestReceivableCurrent	2800000	USD
CY2020Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	3700000	USD
	us-gaap	Debt Securities Available For Sale Accrued Interest Writeoff DebtSecuritiesAvailableForSaleAccruedInterestWriteoff	0	USD
	us-gaap	Debt Securities Available For Sale Accrued Interest Writeoff DebtSecuritiesAvailableForSaleAccruedInterestWriteoff	0	USD
CY2021Q3	us-gaap	Investments Investments	1318100000	USD
CY2020Q4	us-gaap	Investments Investments	1069500000	USD
CY2021Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	13000000.0	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	16600000	USD
CY2021Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1300000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2400000	USD
CY2021Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	11200000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	9000000.0	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	25500000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	28000000.0	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	311100000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	425300000	USD
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3200000	USD
CY2020Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3200000	USD
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	314300000	USD
CY2020Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	428500000	USD
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3200000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	11200000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	7400000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	9100000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	6400000	USD
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y6M
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.053
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.058
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3500000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	16800000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	17500000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	17000000.0	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	15500000	USD
CY2021Q3	nbix	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	85400000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	155700000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	33800000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	121900000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	15500000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	106400000	USD
CY2021Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	381200000	USD
CY2020Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	381300000	USD
CY2021Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	3200000	USD
CY2020Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	4000000.0	USD
CY2021Q3	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	47300000	USD
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	59400000	USD
CY2021Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	330700000	USD
CY2020Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	317900000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	22500000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-57600000	USD
	us-gaap	Net Income Loss NetIncomeLoss	96900000	USD
	us-gaap	Net Income Loss NetIncomeLoss	59400000	USD
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94700000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	93300000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94500000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	93000000.0	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97700000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	93300000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97900000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	98000000.0	shares
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.24
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.64
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.23
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.99
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.61
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4500000	shares
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10900000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4000000.0	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2300000	shares

Files In Submission

Name	View Source	Status
0000914475-21-000058-index-headers.html	Edgar Link	pending
0000914475-21-000058-index.html	Edgar Link	pending
0000914475-21-000058.txt	Edgar Link	pending
0000914475-21-000058-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nbix-20210930.htm	Edgar Link	pending
nbix-20210930.xsd	Edgar Link	pending
nbix-20210930exhibit311.htm	Edgar Link	pending
nbix-20210930exhibit312.htm	Edgar Link	pending
nbix-20210930exhibit32.htm	Edgar Link	pending
nbix-20210930_cal.xml	Edgar Link	unprocessable
nbix-20210930_def.xml	Edgar Link	unprocessable
nbix-20210930_htm.xml	Edgar Link	completed
nbix-20210930_lab.xml	Edgar Link	unprocessable
nbix-20210930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NBIX
NEUROCRINE BIOSCIENCES INC Stock $nbix

2021 Q4 Form 10-Q Financial Statement

#000091447521000058 Filed on November 01, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NBIX NEUROCRINE BIOSCIENCES INC Stock $nbix

2021 Q4 Form 10-Q Financial Statement

#000091447521000058 Filed on November 01, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NBIX
NEUROCRINE BIOSCIENCES INC Stock $nbix